The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Fingolimod phosphate promotes the neuroprotective effects of microglia
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175 · cited 1×
“Some of these monocyte-lineage cells are derived from the yolk sac (Ginhoux et al., 2010).”
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 7×
“TNF- IL-1 IL-6 GAPDH IL-6 (pg/ml) IL-1 (pg/ml) 0 30 60 90 120 150 LPS (1 µg/ml) FTY720 (nM) TNF-(pg/ml) b 0 3000 6000 9000 12000 15000 0 500 1000 1500 2000 2500 3000 LPS (1 µg/ml) FTY720 (nM) LPS (1 µg/ml) FTY720 (nM) LPS (1 µg/ml) FTY720 (nM) * a * * * * * * c d - 0 - 1 - 10 - 100 + 0 + 1 + 10 + 100 - 0 - 1 - 10 - 10…”
InfluentialLymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Signaling in innate immunity and inflammation
Newton, K., & Dixit, V. M. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006049 · Cited by 1,513 · cited 2×
“Activation of NF-κB induces the expressions of proinflammatory cytokines (Newton and Dixit, 2012), whereas inhibition of HDACs suppresses NF-κB activation resulting in downregulation of pro-inflammatory cytokines (Furumai et al., 2011) and promotes the expressions of neurotrophic factors (Wu et…”
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 2×
“Microglial activation is thought to contribute to the progression of various neurologic disorders, such as MS, spinal cord injury, stroke, amyotrophic lateral sclerosis, and Alzheimer's disease (Yrjanheikki et al., 1998; Wu et al., 2002; Zhu et al., 2002; Stirling et al., 2004; Boillee et al., 2006; Seabrook et al., 2…”
Sphingosine-1-phosphate signaling and its role in disease
Maceyka, M., Harikumar, K. B., Milstien, S., & Spiegel, S. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.003 · Cited by 1,039 · cited 2×
“Signaling pathways downstream of S1P 1 modulate a variety of transcription factors, including upregulation of nuclear factor-κB (NF-κB) activity and downregulation of histone deacetylase (HDAC) activity (Lee et al., 2010; Maceyka et al., 2012).”
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 2×
“Microglial activation is thought to contribute to the progression of various neurologic disorders, such as MS, spinal cord injury, stroke, amyotrophic lateral sclerosis, and Alzheimer's disease (Yrjanheikki et al., 1998; Wu et al., 2002; Zhu et al., 2002; Stirling et al., 2004; Boillee et al., 2006; Seabrook et al., 2…”
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796 · cited 2×
“Therefore, inhibiting neurotoxic microglial activation may be a useful therapeutic strategy for MS. Fingolimod can pass through blood–brain-barrier, and effects on CNS cells have been recently reported (Brinkmann, 2009; Chun and Hartung, 2010; Cohen and Chun, 2011).”
Cited by
Modulators of microglial activation and polarization after intracerebral haemorrhage
Lan, X., Han, X., Li, Q., Yang, Q.-W., & Wang, J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.69 · Cited by 915
An update on the biology of sphingosine 1-phosphate receptors
Blaho, V. A., & Hla, T. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046300 · Cited by 516
Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets
Tschoe, C., Bushnell, C. D., Duncan, P. W., Alexander-Miller, M. A., & Wolfe, S. Q. (2020) · Journal of Stroke · doi:10.5853/jos.2019.02236 · Cited by 490
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
Subramaniam, S. R., & Federoff, H. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00176 · Cited by 347
Qin, C., Fan, W.-H., Liu, Q., Shang, K., Murugan, M., Wu, L.-J., Wang, W., & Tian, D.-S. (2017) · Stroke · doi:10.1161/strokeaha.117.018505 · Cited by 334
Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation
Xue, M., & Yong, V. W. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30364-1 · Cited by 323
Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis
Mandolesi, G., Gentile, A., Musella, A., Fresegna, D., De Vito, F., Bullitta, S., Sepman, H., Marfia, G. A., & Centonze, D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.222 · Cited by 286
Microglia in multiple sclerosis: Friend or foe
Guerrero, B. L., & Sicotte, N. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00374 · Cited by 215
Microglia in multiple sclerosis: protectors turn destroyers
Yong, V. W. (2022) · Neuron · doi:10.1016/j.neuron.2022.06.023 · Cited by 185
Glia Crosstalk in Neuroinflammatory Diseases
Bernaus, A., Blanco, S., & Sevilla, A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00209 · Cited by 157
Chun, J., Kihara, Y., Jonnalagadda, D., & Blaho, V. A. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021358 · Cited by 131
Miguez, A., García-Díaz Barriga, G., Brito, V., Straccia, M., Giralt, A., Ginés, S., Canals, J. M., & Alberch, J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv218 · Cited by 126
Wesselingh, R., Butzkueven, H., Buzzard, K., Tarlinton, D., O'Brien, T. J., & Monif, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02066 · Cited by 83
“Aside from its action on lymphocyte trafficking Fingolimod also decreases pro-inflammatory cytokine production and increases the production of neuroprotective molecules produced by activated microglia (33).”
BackgroundFingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis
Potenza, R. L., De Simone, R., Armida, M., Mazziotti, V., Pèzzola, A., Popoli, P., & Minghetti, L. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0462-2 · Cited by 69
Colombo, E., Bassani, C., De Angelis, A., Ruffini, F., Ottoboni, L., Comi, G., Martino, G., & Farina, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00635 · Cited by 66
Metadata
- Authors
- Noda, H., Takeuchi, H., Mizuno, T., & Suzumura, A.
- Venue
- Journal of Neuroimmunology
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 256
- Issue
- 1-2
- Pages
- 13-18
- ISSN
- 0165-5728 (ISSN-L)
- OpenAlex
- W2013555370
- Cited by
- 211
- References
- 15
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.